Bengaluru: OneSource Specialty Pharma Limited, a leading specialty pharma Contract Development and Manufacturing Organization (CDMO), has signed a manufacturing alliance with German-based Formycon AG to produce its biosimilars. According to the agreement, OneSource will manufacture biosimilars for Formycon’s Drug Substance (DS) and Drug Product(DP) at its state-of-the-art manufacturing facilities in Bangalore. This partnership will support Formycon’s manufacturing of biosimilars for the global markets.
The partnership aims to advance global access to biosimilars through reliable, high-quality, and scalable manufacturing. OneSource offers end-to-end biologics manufacturing expertise that complements Formycon’s biosimilar requirements for the global markets. Its integrated biologics platform offers cell line development that includes commercial fill finish, five manufacturing facilities approved by the USFDA and EMA, and extensive expertise across sterile injectables, biologics and drug-device combinations.
“We are delighted to partner with Formycon, one of the world’s leading biosimilar developers with a proven track record of bringing high-quality biosimilars to global markets. This partnership brings together Formycon’s development expertise and OneSource’s integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide. It also reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacture of world-class biologics.” Neeraj Sharma, Managing Director & CEO, OneSource Specialty Pharma, said in a press release.
“Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency. Together, we aim to broaden sustainable global access to life-changing biosimilar therapies.” Dr. Stefan Glombitza, Chief Executive Officer of Formycon AG, added.
